Harrow (HROW) Notes Payables (2011 - 2025)

Harrow (HROW) recorded quarterly Notes Payables of $183.6 million in Q2 2025, up 69.53% quarter-over-quarter from $108.3 million in Q1 2025.

Harrow (HROW) Notes Payables (2011 - 2025) Analysis & Trends

Harrow's Notes Payables history runs 10 years deep, the most recent figure standing at $183.6 million for Q2 2025.

In Q2 2025, Notes Payables changed N/A year-over-year to $183.6 million; the TTM figure through Jun 2025 stood at $183.6 million (changed N/A YoY), while the FY2020 annual figure was $3.9 million, up 119.98% from the prior year.
Notes Payables was $183.6 million for Q2 2025 at Harrow, up from $108.3 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $183.6 million in Q2 2025 to a low of -$3.7 million in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Harrow	1.25 Bn	1.15 Bn	27.05 Mn

Download Data